RxDoctor Payments Data

Marwan Iskandarani, MD

Gastroenterology · North Miami Beach, FLNPI 1255386470

Payments from drug & device makers

$667in general payments, 2019–2025

Across 31 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$189
  • Olympus America Inc.$119
  • QOL Medical, LLC$100
  • Phathom Pharmaceuticals, Inc.$87
  • Redhill Biopharma Inc.$52
  • Intercept Pharmaceuticals, Inc.$28
  • plus $92 from 5 others

What the payments were for

  • Food & beverage$667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$667 in reported general payments places this provider in the 20th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$39,504
Medicare patients
94
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide81$46,064
Bismuth-Metronidazole-TetracycBismuth/Metronid/Tetracycline29$18,785
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg750$16,874
VemlidyTenofovir Alafenamide12$16,080
BaracludeEntecavir11$14,795
Mesalamine ErMesalamine43$8,008
Pantoprazole Sodium975$7,049
Dexlansoprazole DrDexlansoprazole21$3,904
Esomeprazole Magnesium163$3,789
Ursodiol14$3,434
Mesalamine15$3,264
Balsalazide Disodium15$2,397
Lansoprazole100$2,355
Tetracycline Hcl15$2,067
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates28$1,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$189$16,08012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →